Multivariate analysis of adverse prognostic factors associated with EFS, OS, and PFS
| Variable . | EFS . | OS . | PFS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Estimated HR . | 95%CI . | P . | Estimated HR . | 95%CI . | P . | Estimated HR . | 95%CI . | P . | |
| CML duration ≥ 12 mo | 4.5 | 2.3-8.7 | .000 | 3.4 | 1.4-7.9 | .005 | 5.5 | 1.9-15.8 | .002 |
| Hemoglobin < 100 g/L | 2.0 | 1.2-3.5 | .009 | 2.3 | 1.2-4.4 | .009 | 2.0 | 1.0-3.8 | .036 |
| PB blasts ≥ 5% | 2.5 | 1.0-6.0 | .041 | 3.5 | 1.5-8.3 | .005 | |||
| BM blasts ≥ 10% | 2.0 | 1.1-3.7 | .029 | ||||||
| Imatinib therapy | 8.6 | 2.0-37.0 | .004 | ||||||
| Variable . | EFS . | OS . | PFS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Estimated HR . | 95%CI . | P . | Estimated HR . | 95%CI . | P . | Estimated HR . | 95%CI . | P . | |
| CML duration ≥ 12 mo | 4.5 | 2.3-8.7 | .000 | 3.4 | 1.4-7.9 | .005 | 5.5 | 1.9-15.8 | .002 |
| Hemoglobin < 100 g/L | 2.0 | 1.2-3.5 | .009 | 2.3 | 1.2-4.4 | .009 | 2.0 | 1.0-3.8 | .036 |
| PB blasts ≥ 5% | 2.5 | 1.0-6.0 | .041 | 3.5 | 1.5-8.3 | .005 | |||
| BM blasts ≥ 10% | 2.0 | 1.1-3.7 | .029 | ||||||
| Imatinib therapy | 8.6 | 2.0-37.0 | .004 | ||||||
HR indicates hematological response; PB, peripheral blood; and BM, bone marrow